SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Active, not recruiting · NCT05642780 · Registry updated 2025-10-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Solid Tumor | Active, not recruiting | Phase 2 | 2025-10-14 | NCT05642780 |
6 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Clario | 1 |
| Discovery Life Sciences, LLC | 1 |
| Frontage Laboratories, Inc. | 1 |
| Klus Pharma Inc. | 3 |
| Myriad Genetics, Inc. | 5 |
| Ventana Medical Systems, Inc | 3 |
48 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.